

CITATION REPORT

List of articles citing

Side effects of medical therapy for chronic hepatitis C

DOI: 10.1016/s1665-2681(19)32118-0
Annals of Hepatology, 2004, 3, 5-10.

Source: <https://exaly.com/paper-pdf/36317314/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. <i>Clinics in Liver Disease</i> , 2005 , 9, 453-71, vii-viii	4.6	16
31	Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. <i>Infectious Disease Clinics of North America</i> , 2006 , 20, 115-35	6.5	4
30	Use of ribavirin in patients with chronic HCV genotype 1: when enough is really enough. <i>Gastroenterology</i> , 2006 , 131, 1339-41	13.3	5
29	Manejo de los efectos adversos del tratamiento. <i>Gastroenterología Y Hepatología</i> , 2006 , 29, 184-189	0.9	4
28	Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2006 , 18, 1057-63	2.2	43
27	Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders. <i>Current Gastroenterology Reports</i> , 2006 , 8, 46-52	5	17
26	Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. <i>Current Hepatitis Reports</i> , 2006 , 5, 114-120		
25	Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions. <i>European Journal of Gastroenterology and Hepatology</i> , 2006 , 18, 1039-42	2.2	6
24	Hepatitis C virus chronic infection and oral lichen planus: an Italian case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2007 , 19, 647-52	2.2	23
23	Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. <i>Aids</i> , 2007 , 21, 1855-65	3.5	30
22	Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. <i>Gastroenterology</i> , 2007 , 132, 103-12	13.3	173
21	Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. <i>Hepatology</i> , 2007 , 46, 371-9	11.2	175
20	Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. <i>International Journal of Drug Policy</i> , 2008 , 19, 71-8	5.5	39
19	Optimizing the current therapy for chronic hepatitis C virus: peginterferon and ribavirin dosing and the utility of growth factors. <i>Clinics in Liver Disease</i> , 2008 , 12, 487-505, vii	4.6	16
18	Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008 , 22, 376-80		20
17	A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. <i>BMC Gastroenterology</i> , 2009 , 9, 5	3	47
16	What future for ribavirin?. <i>Liver International</i> , 2009 , 29 Suppl 1, 68-73	7.9	22

15	Immune-mediated adverse drug reactions. <i>Chemical Research in Toxicology</i> , 2009 , 22, 24-34	4	83
14	Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response. <i>Journal of Medical Virology</i> , 2010 , 82, 49-56	19.7	24
13	Acquired Haemolytic Anaemias. 2010 , 158-175		
12	Interferon-free regimens: the near future, the likely and the not so likely. <i>Clinics in Liver Disease</i> , 2011 , 15, 665-75	4.6	5
11	Serum ferritin levels in chronic hepatitis C patients during antiviral therapy and prediction of treatment response. <i>Scandinavian Journal of Infectious Diseases</i> , 2012 , 44, 761-5		5
10	Pityriasis rosea associated with pegylated interferon alfa and ribavirin treatment in a patient with chronic hepatitis C. <i>Balkan Medical Journal</i> , 2013 , 30, 253-4	1.5	2
9	The role of interferon in the new era of hepatitis C treatments. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014 , 8, 649-56	4.2	5
8	Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. <i>Liver International</i> , 2015 , 35, 79-89	7.9	21
7	Meta-Analysis of Combination Therapy of Chinese Herbs Plus Interferon and Ribavirin in Patients with Chronic Hepatitis C. <i>Medical Science Monitor</i> , 2016 , 22, 1817-26	3.2	3
6	Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C. <i>Current Therapeutic Research</i> , 2017 , 85, 20-28	2.4	1
5	Engagement in the Hepatitis C care continuum among people who use drugs. <i>Journal of Substance Use</i> , 2020 , 25, 343-349	0.8	0
4	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021 , 28, 9	13.3	52
3	Cytopenias: How they Limit Therapy and Potential Correction. 160-168		
2	Erythrocyte Membrane Protein Band 3 Predicts Interferon Ribavirin-Induced Anemia. <i>Open Journal of Regenerative Medicine</i> , 2019 , 08, 5-16	1.1	
1	Phase 1 Clinical Trial of PPMX-T003, a Novel Human Monoclonal Antibody Specific for Transferrin Receptor 1, to Evaluate Its Safety, Pharmacokinetics, and Pharmacodynamics.		1